CBIO (STOCKS)
Crescent Biopharma, Inc. Common Stock
$17.990000
-0.180000 (-0.99%)
Prev close: $18.170000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Joshua T. Brumm
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $495.75M
- Employees
- 44
- P/E (TTM)
- -1.17
- P/B (TTM)
- 2.52
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $10.84M |
| Benefits Costs and Expenses | $162.79M |
| Costs And Expenses | $162.79M |
| Operating Expenses | $163.48M |
| Research and Development | $138.09M |
| Other Operating Expenses | $25.39M |
| Operating Income/Loss | -$152.63M |
| Income/Loss From Continuing Operations After Tax | -$153.94M |
| Income/Loss From Continuing Operations Before Tax | -$151.94M |
| Income Tax Expense/Benefit | $2.00M |
| Income Tax Expense/Benefit, Current | $2.00M |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$153.94M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$153.94M |
| Net Income/Loss Available To Common Stockholders, Basic | -$133.45M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | -$40.99M |
| Preferred Stock Dividends And Other Adjustments | -$20.50M |
| Undistributed Earnings/Loss Allocated To Participating Securities, Basic | -$20.50M |
| Assets | $240.29M |
| Current Assets | $236.66M |
| Noncurrent Assets | $3.64M |
| Fixed Assets | $846.00K |
| Other Non-current Assets | $2.79M |
| Liabilities | $37.28M |
| Current Liabilities | $36.07M |
| Wages | $5.12M |
| Other Current Liabilities | $30.95M |
| Noncurrent Liabilities | $1.21M |
| Equity | $203.01M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $203.01M |
| Liabilities And Equity | $240.29M |
| Net Cash Flow From Operating Activities | -$71.53M |
| Net Cash Flow From Operating Activities, Continuing | -$71.53M |
| Net Cash Flow From Investing Activities | -$72.92M |
| Net Cash Flow From Investing Activities, Continuing | -$72.92M |
| Net Cash Flow From Financing Activities | $322.98M |
| Net Cash Flow From Financing Activities, Continuing | $322.98M |
| Net Cash Flow | $178.53M |
| Net Cash Flow, Continuing | $178.53M |
| Comprehensive Income/Loss | -$153.94M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$153.94M |
| Other Comprehensive Income/Loss | -$153.94M |